{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INCB028050&page=2", "query": { "intervention": "INCB028050", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INCB028050&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T01:58:31.398Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03026504", "title": "Baricitinib in Relapsing Giant Cell Arteritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arteritis, Giant Cell" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew J Koster", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 15, "start_date": "2017-03-09", "completion_date": "2021-04-12", "has_results": true, "last_update_posted_date": "2022-04-08", "last_synced_at": "2026-09-24T01:58:31.398Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03026504" }, { "nct_id": "NCT03742973", "title": "A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-03-28", "completion_date": "2019-09-26", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-09-24T01:58:31.398Z", "location_count": 10, "location_summary": "Coronado, California • Sacramento, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03742973" }, { "nct_id": "NCT03915964", "title": "A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "TNF Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2659, "start_date": "2019-04-25", "completion_date": "2025-05-28", "has_results": true, "last_update_posted_date": "2026-06-24", "last_synced_at": "2026-09-24T01:58:31.398Z", "location_count": 81, "location_summary": "Flagstaff, Arizona • Gilbert, Arizona • Glendale, Arizona + 69 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03915964" }, { "nct_id": "NCT01711359", "title": "A Study in Participants With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Baricitinib Placebo", "type": "DRUG" }, { "name": "MTX Placebo", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 588, "start_date": "2012-11", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2019-09-19", "last_synced_at": "2026-09-24T01:58:31.398Z", "location_count": 47, "location_summary": "Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "El Cajon", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01711359" }, { "nct_id": "NCT05003310", "title": "ConsideRAte Study - Splenic Stimulation for RA", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Active Stimulation", "type": "DEVICE" }, { "name": "Sham Stimulation", "type": "DEVICE" }, { "name": "Baricitinib", "type": "DRUG" }, { "name": "Background Treatment", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Galvani Bioelectronics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "22 Years to 75 Years" }, "enrollment_count": 28, "start_date": "2021-10-19", "completion_date": "2032-04", "has_results": false, "last_update_posted_date": "2024-05-22", "last_synced_at": "2026-09-24T01:58:31.398Z", "location_count": 12, "location_summary": "Anniston, Alabama • Covina, California • Whittier, California + 8 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Covina", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Hagerstown", "state": "Maryland" }, { "city": "Brooklyn", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05003310" }, { "nct_id": "NCT03570749", "title": "A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alopecia Areata" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 784, "start_date": "2018-09-24", "completion_date": "2025-01-29", "has_results": true, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-09-24T01:58:31.398Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03570749" }, { "nct_id": "NCT04692493", "title": "RA-PRO PRAGMATIC TRIAL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "targeted synthetic DMARD class", "type": "DRUG" }, { "name": "non-TNFi-biologic class", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 924, "start_date": "2021-09-22", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-09-24T01:58:31.398Z", "location_count": 48, "location_summary": "Auburn, Alabama • Birmingham, Alabama • Peoria, Arizona + 41 more", "locations": [ { "city": "Auburn", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04692493" }, { "nct_id": "NCT04401579", "title": "Adaptive COVID-19 Treatment Trial 2 (ACTT-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1033, "start_date": "2020-05-08", "completion_date": "2020-07-31", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-09-24T01:58:31.398Z", "location_count": 53, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04401579" }, { "nct_id": "NCT07262983", "title": "Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hyper IgE Syndrome From STAT3 Mutation", "Job s Syndrome", "HIES", "Lupus", "Atopic Dermatitis" ], "interventions": [ { "name": "baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 20, "start_date": "2026-09-28", "completion_date": "2030-10-01", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-09-24T01:58:31.398Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07262983" }, { "nct_id": "NCT04901325", "title": "Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pyoderma Gangrenosum", "Skin Diseases", "Wound Heal", "Pyoderma", "Skin Ulcer" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 5, "start_date": "2023-10-03", "completion_date": "2025-05-07", "has_results": false, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-09-24T01:58:31.398Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04901325" } ] }